160 related articles for article (PubMed ID: 23916555)
1. PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.
Lyoumi S; Lefebvre T; Karim Z; Gouya L; Puy H
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):439-41. PubMed ID: 23916555
[No Abstract] [Full Text] [Related]
2. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
[TBL] [Abstract][Full Text] [Related]
3. [Antitubercular drug-induced liver injuries].
Guo Y; Cui D
Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
[No Abstract] [Full Text] [Related]
4. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
5. [Liver damage from tuberculosis treatment].
Keiner F
Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
[No Abstract] [Full Text] [Related]
6. Adverse effects of antituberculosis drugs.
Girling DJ
Drugs; 1982; 23(1-2):56-74. PubMed ID: 6459920
[No Abstract] [Full Text] [Related]
7. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice.
Chen X; Xu J; Zhang C; Yu T; Wang H; Zhao M; Duan ZH; Zhang Y; Xu JM; Xu DX
Eur J Pharmacol; 2011 May; 659(1):53-60. PubMed ID: 21419764
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and pathological analysis of liver injury resulting from rifampin and isoniazid].
Xing T; Chen J; Zhang G
Zhonghua Jie He He Hu Xi Za Zhi; 1997 Feb; 20(1):33-5. PubMed ID: 10072800
[TBL] [Abstract][Full Text] [Related]
9. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
10. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
11. [Comprehensive view of hepatitis and the other reactions secondary to antituberculosis chemotherapy].
Girling DJ
Bull Int Union Tuberc; 1980; 55(1-2):9-13. PubMed ID: 7214064
[No Abstract] [Full Text] [Related]
12. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects of antitubercular agents].
Peng DH; Wang ZX
Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1985 Dec; 8(6):367-71. PubMed ID: 2942371
[No Abstract] [Full Text] [Related]
14. The side effects and interactions of antituberculosis drugs.
Addington WW
Chest; 1979 Dec; 76(6 Suppl):782-4. PubMed ID: 510025
[No Abstract] [Full Text] [Related]
15. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
16. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
17. An unusual recurrence of antitubercular drug induced hepatotoxicity in a child.
Bhatia S; Tullu MS; Kannan S; Gogtay NJ; Thatte UM; Lahiri KR
J Postgrad Med; 2011; 57(2):147-52. PubMed ID: 21654145
[No Abstract] [Full Text] [Related]
18. [Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model].
Leinweber B; Mahrt R
Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():300-3. PubMed ID: 1029192
[No Abstract] [Full Text] [Related]
19. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
